Inventor · disambiguated record
John F. Ross
Also filed as: ROSS JOHN · ROSS JOHN F
9 granted patents·37 pending applications·28 citations·filing 1989–2025
84Inventor score
Files withCUE BIOPHARMA INC40BRISTOL MYERS SQUIBB CO2PERMEON BIOLOG INC2BOWDISH KATHERINE S1CROSSLINK THERAPEUTICS INC1
Top patents by PatentIndex Score
46 records- 0196US11878062B2Multimeric T-cell modulatory polypeptides and methods of use thereofCUE BIOPHARMA INC·Filed 2023·Granted Jan 23, 2024·9 cites·4 claims
- 0295US11692018B2TGF-β polypeptidesCUE BIOPHARMA INC·Filed 2022·Granted Jul 4, 2023·2 cites·23 claims
- 0394US12029782B2MHC class II T-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (T1D) and methods of use thereofCUE BIOPHARMA INC·Filed 2023·Granted Jul 9, 2024·1 cites·2 claims
- 0493US12006348B2T-cell modulatory multimeric polypeptide with conjugation sites and methods of use thereofCUE BIOPHARMA INC·Filed 2020·Granted Jun 11, 2024·3 cites·8 claims
- 0586US12257311B2Multimeric T-cell modulatory polypeptides and methods of use thereofCUE BIOPHARMA INC·Filed 2023·Granted Mar 25, 2025·0 cites·33 claims
- 0685US12485184B2Multimeric T-cell modulatory polypeptides and methods of use thereofCUE BIOPHARMA INC·Filed 2023·Granted Dec 2, 2025·0 cites·1 claims
- 0784US2025206794A1TGF-Beta PolypeptidesCUE BIOPHARMA INC·Filed 2024·Application pending·0 cites
- 0882US12485183B2Multimeric T-cell modulatory polypeptides and methods of use thereofCUE BIOPHARMA INC·Filed 2022·Granted Dec 2, 2025·0 cites·1 claims
- 0980US2024299515A1Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereofCUE BIOPHARMA INC·Filed 2024·Application pending·0 cites
- 1078US2024409606A1T-Cell Modulatory Multimeric Polypeptide with Conjugation Sites and Methods of Use ThereofCUE BIOPHARMA INC·Filed 2024·Application pending·0 cites
- 1178US2025120996A1T-cell modulatory polypeptides and methods of use thereofCUE BIOPHARMA INC·Filed 2024·Application pending·0 cites
- 1275US2023321206A1Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereofCUE BIOPHARMA INC·Filed 2023·Application pending·0 cites
- 1371US2024034767A1Antigen-presenting polypeptides and methods of use thereofCUE BIOPHARMA INC·Filed 2023·Application pending·0 cites
- 1469US2025041404A1T Cell Modulatory Polypeptides with Conjugation Sites and Methods of Use ThereofCUE BIOPHARMA INC·Filed 2024·Application pending·0 cites
- 1568US2023064668A1Antigen-Presenting Polypeptides with Chemical Conjugation Sites and Methods of Use ThereofCUE BIOPHARMA INC·Filed 2022·Application pending·0 cites
- 1668US2025270284A1MHC Class II Protein ConstructsCUE BIOPHARMA INC·Filed 2024·Application pending·0 cites
- 1766US2025041396A1T Cell Modulatory Polypeptides with Conjugation Sites and Methods of Use ThereofCUE BIOPHARMA INC·Filed 2024·Application pending·0 cites
- 1864US2024067700A1T-cell modulatory polypeptides and methods of use thereofCUE BIOPHARMA INC·Filed 2023·Application pending·0 cites
- 1964US2024067699A1T-cell modulatory polypeptides and methods of use thereofCUE BIOPHARMA INC·Filed 2023·Application pending·0 cites
- 2063US2022143063A1T-cell modulatory polypeptides and methods of use thereofCUE BIOPHARMA INC·Filed 2022·Application pending·0 cites
- 2163US2023330197A1Mhc class ii t-cell modulatory multimeric polypeptides and methods of use thereofCUE BIOPHARMA INC·Filed 2023·Application pending·0 cites
- 2260US2024197846A1Antigen-Presenting Polypeptides with Chemical Conjugation Sites and Methods of Use ThereofCUE BIOPHARMA INC·Filed 2022·Application pending·0 cites
- 2360US2024270815A1Antigen Presenting Polypeptide Complexes and Methods of Use ThereofCUE BIOPHARMA INC·Filed 2022·Application pending·0 cites
- 2459US2024189403A1Antigen-Presenting Polypeptides with Chemical Conjugation Sites and Methods of Use ThereofCUE BIOPHARMA INC·Filed 2022·Application pending·0 cites
- 2559US2024190933A1Antigen Presenting Polypeptide Complexes Bearing TGF-Beta and Methods of Use ThereofCUE BIOPHARMA INC·Filed 2022·Application pending·0 cites
- 2659US2024181025A1Antigen Presenting Polypeptide Complexes Bearing TGF-Beta and Methods of Use ThereofCUE BIOPHARMA INC·Filed 2022·Application pending·0 cites
- 2758US2023416321A1TGF-Beta PolypeptidesCUE BIOPHARMA INC·Filed 2021·Application pending·0 cites
- 2858US2020407416A1Antigen-Presenting Polypeptides with Chemical Conjugation Sites and Methods of Use ThereofCUE BIOPHARMA INC·Filed 2020·Application pending·0 cites
- 2958US2020172595A1Antigen-presenting polypeptides and methods of use thereofCUE BIOPHARMA INC·Filed 2020·Application pending·0 cites
- 3057US2022135645A1Antigen-Presenting Polypeptides with Chemical Conjugation Sites and Methods of Use ThereofCUE BIOPHARMA INC·Filed 2021·Application pending·0 cites
- 3157US2024082411A1T-Cell Modulatory Polypeptides with Conjugation Sites and Methods of Use ThereofCUE BIOPHARMA INC·Filed 2021·Application pending·0 cites
- 3257US2023414777A1Antigen Presenting Polypeptide Complexes and Methods of Use ThereofCUE BIOPHARMA INC·Filed 2021·Application pending·0 cites
- 3356US5028536AAntitumor antibiotic BMY-41339BRISTOL MYERS SQUIBB CO·Filed 1989·Granted Jul 2, 1991·11 cites·1 claims
- 3456US2022008467A1T-Cell Modulatory Multimeric Polypeptides with Conjugation Sites and Methods of Use ThereofCUE BIOPHARMA INC·Filed 2021·Application pending·0 cites
- 3556US2023218731A1Antigen Presenting Polypeptide Complexes and Methods of Use ThereofCUE BIOPHARMA INC·Filed 2021·Application pending·0 cites
- 3656US2022079985A1T-Cell Modulatory Multimeric Polypeptides with Conjugation Sites and Methods of Use ThereofCUE BIOPHARMA INC·Filed 2021·Application pending·0 cites
- 3756US2021393693A1T-Cell Modulatory Multimeric Polypeptides with Conjugation Sites and Methods of Use ThereofCUE BIOPHARMA INC·Filed 2021·Application pending·0 cites
- 3855US2022135644A1Antigen-Presenting Polypeptides with Chemical Conjugation Sites and Methods of Use ThereofCUE BIOPHARMA INC·Filed 2021·Application pending·0 cites
- 3954US2023117521A1T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereofCUE BIOPHARMA INC·Filed 2021·Application pending·0 cites
- 4054US2023279076A1T-Cell Modulatory Polypeptides with Conjugation Sites and Methods of Use ThereofCUE BIOPHARMA INC·Filed 2021·Application pending·0 cites
- 4153US2023201335A1Antigen Presenting Polypeptide Complexes and Methods of Use ThereofCUE BIOPHARMA INC·Filed 2021·Application pending·0 cites
- 4248US2025257148A1ATP-Dependent Agonists of Immune Cells Function as Anticancer AgentsCROSSLINK THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4344US2016031985A1Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of useBOWDISH KATHERINE S·Filed 2014·Application pending·0 cites
- 4441US2014271640A1FGF-10 ComplexesPERMEON BIOLOG INC·Filed 2013·Application pending·0 cites
- 4538US2015307576A1Fgf-10 complexesPERMEON BIOLOG INC·Filed 2013·Application pending·0 cites
- 4634US5086045AAntitumor antibioticBRISTOL MYERS SQUIBB CO·Filed 1990·Granted Feb 4, 1992·2 cites·3 claims
Join the waitlist — get patent alerts
Get an alert when John F. Ross files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →